Spinal Dysraphism

Respiratory syncytial virus is the most common cause of hospitalization in U.S. infants, accounting for 58,000–80,000 hospitalizations and 200–300 deaths in children under 5 each year. Two prevention strategies — the long-acting monoclonal antibody nirsevimab (Beyfortus) for infants, and the maternal RSVpreF vaccine (Abrysvo) given in pregnancy — now offer Louisiana pediatricians and obstetric clinicians powerful tools to prevent severe lower respiratory tract disease. This clinical reference, originally prepared by Joseph A. Bocchini, Jr., MD, FAAP (Tulane University Department of Pediatrics / Willis-Knighton Health System) for the LA AAP, summarizes ACIP and AAP recommendations on who should receive nirsevimab, when, and how it pairs with maternal vaccination.

DownloAd the Spinal Dysraphism Presentation